Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive
breast cancer has led to dramatic improvements in survival in both early and advanced …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Brain, the major organ of the central nervous system controls and processes most of body
activities. Therefore, the most aggressive brain tumor–glioblastoma and metastases from …

Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study,
progression-free survival was significantly longer with trastuzumab emtansine versus …

Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …

Abstract Human Epidermal Growth Factor Receptor 2-positive breast cancer (HER2+ BC) is
defined by increased amplification of the ERBB2/neu oncogene and/or overexpression of its …